Aprea Therapeutics Inc (NAS:APRE)

$ 5.8 -0.09 (-1.53%) Market Cap: 31.50 Mil Enterprise Value: 3.20 Mil PE Ratio: 0 PB Ratio: 1.30 GF Score: 42/100

Aprea Therapeutics Inc to Host Key Opinion Leader (KOL) Event Transcript
Oct 31, 2023
Aprea Therapeutics Inc Annual Shareholders Meeting Transcript
Aug 23, 2023
Aprea Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Aprea Therapeutics Inc Acquisition Of Atrin Pharmaceuticals Inc M&A Call Transcript
May 16, 2022
Aprea Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Aprea Therapeutics Inc Myeloid Malignancy Regulatory Update Call Transcript
Aug 06, 2021
Aprea Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 09, 2021
Aprea Therapeutics Inc R&D Update - Corporate Call Transcript
Apr 22, 2021
Aprea Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021
Aprea Therapeutics, Inc. - Special Call Transcript
Oct 30, 2020
Aprea Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2020
Aprea Therapeutics Inc at 38th Annual J.P Morgan Healthcare Conference Transcript
Jan 14, 2020

Aprea Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2022 / 04:15PM GMT

Release Date Price: $51.4 (-6.88%)

Transcript 8-K

Jessica Macomber Fye

JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan. And we're continuing the 40th JPMorgan Healthcare Conference today with Aprea. I'm joined by the company's CEO, Chris Schade, who's going to give a presentation on the business, and then, we're going to go into some Q&A. (Operator Instructions)

So with that, let me pass it over to Chris.

Christian S. Schade

Aprea Therapeutics, Inc. - President, CEO & Chairman

Thank you, Jess. Good morning, everyone. And on behalf of our Aprea team, I'd like to thank JPMorgan for the opportunity to present today and provide an update on Aprea. Before beginning, I'd just like to say, we will be making forward-looking statements, and so, please refer to our filings with the SEC to explain the risks and uncertainties associated with our business.

To begin with, what I'd like to do is provide a presentation overview. Now, very clearly, 2021 was a very challenging year for Aprea. We announced, a

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.